Search results
Merck Shares Climb After Higher-Than-Expected Sales of Cancer Drug Keytruda
The Wall Street Journal· 3 hours agoShares of U.S. drugmaker Merck are up nearly 4% in recent trading after the company said its...
Merck Beats on Earnings a Month After Major Drug Approval. The Stock Is Rising.
Barrons.com· 3 hours agoFEATURE Sales of Merck ‘s blockbuster cancer drug Keytruda jumped 20% in the first quarter of the...
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 6 hours agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Reuters via AOL· 6 hours ago(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecast on the back of...
Merck's stock rises on sales of its blockbuster cancer drug Keytruda
Quartz· 1 hour agoMerck’s stock jumped 3% to about $130 during Thursday morning trading after the New Jersey-based pharmaceutical company reported higher than expected sales of its blockbuster cancer drug < ...
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 3 hours agoMerck stock popped Thursday after the Dow Jones stalwart topped Wall Street's first-quarter views on...
Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Results
Investopedia· 9 hours agoMerck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported...
Will Higher Keytruda Sales Drive Merck's Q1
Forbes· 1 day agoMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. As usual, Keytruda will be the driving growth for Merck with quarterly sales...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 6 hours agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 5 hours agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
